 | • レポートコード：MRC2-11QY01549 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、150ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は免疫チェックポイント阻害剤のグローバル市場について調査・分析したレポートです。種類別（PD-1/PD-L1、CTLA-4）市場規模、用途別（肺がん、結腸直腸がん、乳がん、前立腺がん、黒色腫、血液がん、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別免疫チェックポイント阻害剤の競争状況、市場シェア ・世界の免疫チェックポイント阻害剤市場：種類別市場規模 2015年-2020年（PD-1/PD-L1、CTLA-4） ・世界の免疫チェックポイント阻害剤市場：種類別市場規模予測 2021年-2026年（PD-1/PD-L1、CTLA-4） ・世界の免疫チェックポイント阻害剤市場：用途別市場規模 2015年-2020年（肺がん、結腸直腸がん、乳がん、前立腺がん、黒色腫、血液がん、その他） ・世界の免疫チェックポイント阻害剤市場：用途別市場規模予測 2021年-2026年（肺がん、結腸直腸がん、乳がん、前立腺がん、黒色腫、血液がん、その他） ・北米の免疫チェックポイント阻害剤市場分析：米国、カナダ ・ヨーロッパの免疫チェックポイント阻害剤市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの免疫チェックポイント阻害剤市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の免疫チェックポイント阻害剤市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの免疫チェックポイント阻害剤市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Bristol Myer Squibb、AstraZeneca、Merck & Co.、Roche / Genentech、Incyte Corporation、NewLink Genetics、ArGEN-X、Seattle Genetics、Pfizer、MacroGenics、Celldex Therapeutics、CureTech、Immutep、Innate Pharma、Sorrento Therapeutics、GlaxoSmithKline、GITR, Inc ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.
Market Analysis and Insights: Global Immune Checkpoint Inhibitors Market
The global Immune Checkpoint Inhibitors market size is projected to reach US$ 14730 million by 2026, from US$ 12550 million in 2020, at a CAGR of 16.1%% during 2021-2026.
Global Immune Checkpoint Inhibitors Scope and Market Size
Immune Checkpoint Inhibitors market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Immune Checkpoint Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Immune Checkpoint Inhibitors market is segmented into
PD-1/PD-L1
CTLA-4
Segment by Application, the Immune Checkpoint Inhibitors market is segmented into
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Other
Regional and Country-level Analysis
The Immune Checkpoint Inhibitors market is analysed and market size information is provided by regions (countries).
The key regions covered in the Immune Checkpoint Inhibitors market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Immune Checkpoint Inhibitors Market Share Analysis
Immune Checkpoint Inhibitors market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Immune Checkpoint Inhibitors business, the date to enter into the Immune Checkpoint Inhibitors market, Immune Checkpoint Inhibitors product introduction, recent developments, etc.
The major vendors covered:
Bristol Myer Squibb
AstraZeneca
Merck & Co.
Roche / Genentech
Incyte Corporation
NewLink Genetics
ArGEN-X
Seattle Genetics
Pfizer
MacroGenics
Celldex Therapeutics
CureTech
Immutep
Innate Pharma
Sorrento Therapeutics
GlaxoSmithKline
GITR, Inc
1 Study Coverage
1.1 Immune Checkpoint Inhibitors Product Introduction
1.2 Market Segments
1.3 Key Immune Checkpoint Inhibitors Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Immune Checkpoint Inhibitors Market Size Growth Rate by Type
1.4.2 PD-1/PD-L1
1.4.3 CTLA-4
1.5 Market by Application
1.5.1 Global Immune Checkpoint Inhibitors Market Size Growth Rate by Application
1.5.2 Lung Cancer
1.5.3 Colorectal Cancer
1.5.4 Breast Cancer
1.5.5 Prostate Cancer
1.5.6 Melanoma
1.5.7 Blood Cancer
1.5.8 Other
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Immune Checkpoint Inhibitors Market Size, Estimates and Forecasts
2.1.1 Global Immune Checkpoint Inhibitors Revenue 2015-2026
2.1.2 Global Immune Checkpoint Inhibitors Sales 2015-2026
2.2 Global Immune Checkpoint Inhibitors, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Immune Checkpoint Inhibitors Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Immune Checkpoint Inhibitors Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Immune Checkpoint Inhibitors Competitor Landscape by Players
3.1 Immune Checkpoint Inhibitors Sales by Manufacturers
3.1.1 Immune Checkpoint Inhibitors Sales by Manufacturers (2015-2020)
3.1.2 Immune Checkpoint Inhibitors Sales Market Share by Manufacturers (2015-2020)
3.2 Immune Checkpoint Inhibitors Revenue by Manufacturers
3.2.1 Immune Checkpoint Inhibitors Revenue by Manufacturers (2015-2020)
3.2.2 Immune Checkpoint Inhibitors Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Immune Checkpoint Inhibitors Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Immune Checkpoint Inhibitors Revenue in 2019
3.2.5 Global Immune Checkpoint Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Immune Checkpoint Inhibitors Price by Manufacturers
3.4 Immune Checkpoint Inhibitors Manufacturing Base Distribution, Product Types
3.4.1 Immune Checkpoint Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Immune Checkpoint Inhibitors Product Type
3.4.3 Date of International Manufacturers Enter into Immune Checkpoint Inhibitors Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Immune Checkpoint Inhibitors Market Size by Type (2015-2020)
4.1.1 Global Immune Checkpoint Inhibitors Sales by Type (2015-2020)
4.1.2 Global Immune Checkpoint Inhibitors Revenue by Type (2015-2020)
4.1.3 Immune Checkpoint Inhibitors Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Immune Checkpoint Inhibitors Market Size Forecast by Type (2021-2026)
4.2.1 Global Immune Checkpoint Inhibitors Sales Forecast by Type (2021-2026)
4.2.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Type (2021-2026)
4.2.3 Immune Checkpoint Inhibitors Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Immune Checkpoint Inhibitors Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Immune Checkpoint Inhibitors Market Size by Application (2015-2020)
5.1.1 Global Immune Checkpoint Inhibitors Sales by Application (2015-2020)
5.1.2 Global Immune Checkpoint Inhibitors Revenue by Application (2015-2020)
5.1.3 Immune Checkpoint Inhibitors Price by Application (2015-2020)
5.2 Immune Checkpoint Inhibitors Market Size Forecast by Application (2021-2026)
5.2.1 Global Immune Checkpoint Inhibitors Sales Forecast by Application (2021-2026)
5.2.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Application (2021-2026)
5.2.3 Global Immune Checkpoint Inhibitors Price Forecast by Application (2021-2026)
6 North America
6.1 North America Immune Checkpoint Inhibitors by Country
6.1.1 North America Immune Checkpoint Inhibitors Sales by Country
6.1.2 North America Immune Checkpoint Inhibitors Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Immune Checkpoint Inhibitors Market Facts & Figures by Type
6.3 North America Immune Checkpoint Inhibitors Market Facts & Figures by Application
7 Europe
7.1 Europe Immune Checkpoint Inhibitors by Country
7.1.1 Europe Immune Checkpoint Inhibitors Sales by Country
7.1.2 Europe Immune Checkpoint Inhibitors Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Immune Checkpoint Inhibitors Market Facts & Figures by Type
7.3 Europe Immune Checkpoint Inhibitors Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Immune Checkpoint Inhibitors by Region
8.1.1 Asia Pacific Immune Checkpoint Inhibitors Sales by Region
8.1.2 Asia Pacific Immune Checkpoint Inhibitors Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Immune Checkpoint Inhibitors Market Facts & Figures by Type
8.3 Asia Pacific Immune Checkpoint Inhibitors Market Facts & Figures by Application
9 Latin America
9.1 Latin America Immune Checkpoint Inhibitors by Country
9.1.1 Latin America Immune Checkpoint Inhibitors Sales by Country
9.1.2 Latin America Immune Checkpoint Inhibitors Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Immune Checkpoint Inhibitors Market Facts & Figures by Type
9.3 Central & South America Immune Checkpoint Inhibitors Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Immune Checkpoint Inhibitors by Country
10.1.1 Middle East and Africa Immune Checkpoint Inhibitors Sales by Country
10.1.2 Middle East and Africa Immune Checkpoint Inhibitors Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Immune Checkpoint Inhibitors Market Facts & Figures by Type
10.3 Middle East and Africa Immune Checkpoint Inhibitors Market Facts & Figures by Application
11 Company Profiles
11.1 Bristol Myer Squibb
11.1.1 Bristol Myer Squibb Corporation Information
11.1.2 Bristol Myer Squibb Description and Business Overview
11.1.3 Bristol Myer Squibb Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bristol Myer Squibb Immune Checkpoint Inhibitors Products Offered
11.1.5 Bristol Myer Squibb Related Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Corporation Information
11.2.2 AstraZeneca Description and Business Overview
11.2.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.2.4 AstraZeneca Immune Checkpoint Inhibitors Products Offered
11.2.5 AstraZeneca Related Developments
11.3 Merck & Co.
11.3.1 Merck & Co. Corporation Information
11.3.2 Merck & Co. Description and Business Overview
11.3.3 Merck & Co. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Merck & Co. Immune Checkpoint Inhibitors Products Offered
11.3.5 Merck & Co. Related Developments
11.4 Roche / Genentech
11.4.1 Roche / Genentech Corporation Information
11.4.2 Roche / Genentech Description and Business Overview
11.4.3 Roche / Genentech Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Roche / Genentech Immune Checkpoint Inhibitors Products Offered
11.4.5 Roche / Genentech Related Developments
11.5 Incyte Corporation
11.5.1 Incyte Corporation Corporation Information
11.5.2 Incyte Corporation Description and Business Overview
11.5.3 Incyte Corporation Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Incyte Corporation Immune Checkpoint Inhibitors Products Offered
11.5.5 Incyte Corporation Related Developments
11.6 NewLink Genetics
11.6.1 NewLink Genetics Corporation Information
11.6.2 NewLink Genetics Description and Business Overview
11.6.3 NewLink Genetics Sales, Revenue and Gross Margin (2015-2020)
11.6.4 NewLink Genetics Immune Checkpoint Inhibitors Products Offered
11.6.5 NewLink Genetics Related Developments
11.7 ArGEN-X
11.7.1 ArGEN-X Corporation Information
11.7.2 ArGEN-X Description and Business Overview
11.7.3 ArGEN-X Sales, Revenue and Gross Margin (2015-2020)
11.7.4 ArGEN-X Immune Checkpoint Inhibitors Products Offered
11.7.5 ArGEN-X Related Developments
11.8 Seattle Genetics
11.8.1 Seattle Genetics Corporation Information
11.8.2 Seattle Genetics Description and Business Overview
11.8.3 Seattle Genetics Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Seattle Genetics Immune Checkpoint Inhibitors Products Offered
11.8.5 Seattle Genetics Related Developments
11.9 Pfizer
11.9.1 Pfizer Corporation Information
11.9.2 Pfizer Description and Business Overview
11.9.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Pfizer Immune Checkpoint Inhibitors Products Offered
11.9.5 Pfizer Related Developments
11.10 MacroGenics
11.10.1 MacroGenics Corporation Information
11.10.2 MacroGenics Description and Business Overview
11.10.3 MacroGenics Sales, Revenue and Gross Margin (2015-2020)
11.10.4 MacroGenics Immune Checkpoint Inhibitors Products Offered
11.10.5 MacroGenics Related Developments
11.1 Bristol Myer Squibb
11.1.1 Bristol Myer Squibb Corporation Information
11.1.2 Bristol Myer Squibb Description and Business Overview
11.1.3 Bristol Myer Squibb Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bristol Myer Squibb Immune Checkpoint Inhibitors Products Offered
11.1.5 Bristol Myer Squibb Related Developments
11.12 CureTech
11.12.1 CureTech Corporation Information
11.12.2 CureTech Description and Business Overview
11.12.3 CureTech Sales, Revenue and Gross Margin (2015-2020)
11.12.4 CureTech Products Offered
11.12.5 CureTech Related Developments
11.13 Immutep
11.13.1 Immutep Corporation Information
11.13.2 Immutep Description and Business Overview
11.13.3 Immutep Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Immutep Products Offered
11.13.5 Immutep Related Developments
11.14 Innate Pharma
11.14.1 Innate Pharma Corporation Information
11.14.2 Innate Pharma Description and Business Overview
11.14.3 Innate Pharma Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Innate Pharma Products Offered
11.14.5 Innate Pharma Related Developments
11.15 Sorrento Therapeutics
11.15.1 Sorrento Therapeutics Corporation Information
11.15.2 Sorrento Therapeutics Description and Business Overview
11.15.3 Sorrento Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Sorrento Therapeutics Products Offered
11.15.5 Sorrento Therapeutics Related Developments
11.16 GlaxoSmithKline
11.16.1 GlaxoSmithKline Corporation Information
11.16.2 GlaxoSmithKline Description and Business Overview
11.16.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.16.4 GlaxoSmithKline Products Offered
11.16.5 GlaxoSmithKline Related Developments
11.17 GITR, Inc
11.17.1 GITR, Inc Corporation Information
11.17.2 GITR, Inc Description and Business Overview
11.17.3 GITR, Inc Sales, Revenue and Gross Margin (2015-2020)
11.17.4 GITR, Inc Products Offered
11.17.5 GITR, Inc Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Immune Checkpoint Inhibitors Market Estimates and Projections by Region
12.1.1 Global Immune Checkpoint Inhibitors Sales Forecast by Regions 2021-2026
12.1.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Regions 2021-2026
12.2 North America Immune Checkpoint Inhibitors Market Size Forecast (2021-2026)
12.2.1 North America: Immune Checkpoint Inhibitors Sales Forecast (2021-2026)
12.2.2 North America: Immune Checkpoint Inhibitors Revenue Forecast (2021-2026)
12.2.3 North America: Immune Checkpoint Inhibitors Market Size Forecast by Country (2021-2026)
12.3 Europe Immune Checkpoint Inhibitors Market Size Forecast (2021-2026)
12.3.1 Europe: Immune Checkpoint Inhibitors Sales Forecast (2021-2026)
12.3.2 Europe: Immune Checkpoint Inhibitors Revenue Forecast (2021-2026)
12.3.3 Europe: Immune Checkpoint Inhibitors Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Immune Checkpoint Inhibitors Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Immune Checkpoint Inhibitors Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Immune Checkpoint Inhibitors Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Immune Checkpoint Inhibitors Market Size Forecast by Region (2021-2026)
12.5 Latin America Immune Checkpoint Inhibitors Market Size Forecast (2021-2026)
12.5.1 Latin America: Immune Checkpoint Inhibitors Sales Forecast (2021-2026)
12.5.2 Latin America: Immune Checkpoint Inhibitors Revenue Forecast (2021-2026)
12.5.3 Latin America: Immune Checkpoint Inhibitors Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Immune Checkpoint Inhibitors Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Immune Checkpoint Inhibitors Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Immune Checkpoint Inhibitors Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Immune Checkpoint Inhibitors Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Immune Checkpoint Inhibitors Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Immune Checkpoint Inhibitors Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Immune Checkpoint Inhibitors Market Segments
Table 2. Ranking of Global Top Immune Checkpoint Inhibitors Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Immune Checkpoint Inhibitors Market Size Growth Rate by Type 2020-2026 (MT) & (US$ Million)
Table 4. Major Manufacturers of PD-1/PD-L1
Table 5. Major Manufacturers of CTLA-4
Table 6. Global Immune Checkpoint Inhibitors Market Size Growth Rate by Application 2020-2026 (MT)
Table 7. Global Immune Checkpoint Inhibitors Market Size by Region (MT) & (US$ Million): 2020 VS 2026
Table 8. Global Immune Checkpoint Inhibitors Sales by Regions 2015-2020 (MT)
Table 9. Global Immune Checkpoint Inhibitors Sales Market Share by Regions (2015-2020)
Table 10. Global Immune Checkpoint Inhibitors Revenue by Regions 2015-2020 (US$ Million)
Table 11. Global Immune Checkpoint Inhibitors Sales by Manufacturers (2015-2020) (MT)
Table 12. Global Immune Checkpoint Inhibitors Sales Share by Manufacturers (2015-2020)
Table 13. Global Immune Checkpoint Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 14. Global Immune Checkpoint Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immune Checkpoint Inhibitors as of 2019)
Table 15. Immune Checkpoint Inhibitors Revenue by Manufacturers (2015-2020) (US$ Million)
Table 16. Immune Checkpoint Inhibitors Revenue Share by Manufacturers (2015-2020)
Table 17. Key Manufacturers Immune Checkpoint Inhibitors Price (2015-2020) (USD/Kg)
Table 18. Immune Checkpoint Inhibitors Manufacturers Manufacturing Base Distribution and Headquarters
Table 19. Manufacturers Immune Checkpoint Inhibitors Product Type
Table 20. Date of International Manufacturers Enter into Immune Checkpoint Inhibitors Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Global Immune Checkpoint Inhibitors Sales by Type (2015-2020) (MT)
Table 23. Global Immune Checkpoint Inhibitors Sales Share by Type (2015-2020)
Table 24. Global Immune Checkpoint Inhibitors Revenue by Type (2015-2020) (US$ Million)
Table 25. Global Immune Checkpoint Inhibitors Revenue Share by Type (2015-2020)
Table 26. Immune Checkpoint Inhibitors Average Selling Price (ASP) by Type 2015-2020 (USD/Kg)
Table 27. Global Immune Checkpoint Inhibitors Sales by Application (2015-2020) (MT)
Table 28. Global Immune Checkpoint Inhibitors Sales Share by Application (2015-2020)
Table 29. North America Immune Checkpoint Inhibitors Sales by Country (2015-2020) (MT)
Table 30. North America Immune Checkpoint Inhibitors Sales Market Share by Country (2015-2020)
Table 31. North America Immune Checkpoint Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 32. North America Immune Checkpoint Inhibitors Revenue Market Share by Country (2015-2020)
Table 33. North America Immune Checkpoint Inhibitors Sales by Type (2015-2020) (MT)
Table 34. North America Immune Checkpoint Inhibitors Sales Market Share by Type (2015-2020)
Table 35. North America Immune Checkpoint Inhibitors Sales by Application (2015-2020) (MT)
Table 36. North America Immune Checkpoint Inhibitors Sales Market Share by Application (2015-2020)
Table 37. Europe Immune Checkpoint Inhibitors Sales by Country (2015-2020) (MT)
Table 38. Europe Immune Checkpoint Inhibitors Sales Market Share by Country (2015-2020)
Table 39. Europe Immune Checkpoint Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 40. Europe Immune Checkpoint Inhibitors Revenue Market Share by Country (2015-2020)
Table 41. Europe Immune Checkpoint Inhibitors Sales by Type (2015-2020) (MT)
Table 42. Europe Immune Checkpoint Inhibitors Sales Market Share by Type (2015-2020)
Table 43. Europe Immune Checkpoint Inhibitors Sales by Application (2015-2020) (MT)
Table 44. Europe Immune Checkpoint Inhibitors Sales Market Share by Application (2015-2020)
Table 45. Asia Pacific Immune Checkpoint Inhibitors Sales by Region (2015-2020) (MT)
Table 46. Asia Pacific Immune Checkpoint Inhibitors Sales Market Share by Region (2015-2020)
Table 47. Asia Pacific Immune Checkpoint Inhibitors Revenue by Region (2015-2020) (US$ Million)
Table 48. Asia Pacific Immune Checkpoint Inhibitors Revenue Market Share by Region (2015-2020)
Table 49. Asia Pacific Immune Checkpoint Inhibitors Sales by Type (2015-2020) (MT)
Table 50. Asia Pacific Immune Checkpoint Inhibitors Sales Market Share by Type (2015-2020)
Table 51. Asia Pacific Immune Checkpoint Inhibitors Sales by Application (2015-2020) (MT)
Table 52. Asia Pacific Immune Checkpoint Inhibitors Sales Market Share by Application (2015-2020)
Table 53. Latin America Immune Checkpoint Inhibitors Sales by Country (2015-2020) (MT)
Table 54. Latin America Immune Checkpoint Inhibitors Sales Market Share by Country (2015-2020)
Table 55. Latin Americaa Immune Checkpoint Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 56. Latin America Immune Checkpoint Inhibitors Revenue Market Share by Country (2015-2020)
Table 57. Latin America Immune Checkpoint Inhibitors Sales by Type (2015-2020) (MT)
Table 58. Latin America Immune Checkpoint Inhibitors Sales Market Share by Type (2015-2020)
Table 59. Latin America Immune Checkpoint Inhibitors Sales by Application (2015-2020) (MT)
Table 60. Latin America Immune Checkpoint Inhibitors Sales Market Share by Application (2015-2020)
Table 61. Middle East and Africa Immune Checkpoint Inhibitors Sales by Country (2015-2020) (MT)
Table 62. Middle East and Africa Immune Checkpoint Inhibitors Sales Market Share by Country (2015-2020)
Table 63. Middle East and Africa Immune Checkpoint Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 64. Middle East and Africa Immune Checkpoint Inhibitors Revenue Market Share by Country (2015-2020)
Table 65. Middle East and Africa Immune Checkpoint Inhibitors Sales by Type (2015-2020) (MT)
Table 66. Middle East and Africa Immune Checkpoint Inhibitors Sales Market Share by Type (2015-2020)
Table 67. Middle East and Africa Immune Checkpoint Inhibitors Sales by Application (2015-2020) (MT)
Table 68. Middle East and Africa Immune Checkpoint Inhibitors Sales Market Share by Application (2015-2020)
Table 69. Bristol Myer Squibb Corporation Information
Table 70. Bristol Myer Squibb Description and Major Businesses
Table 71. Bristol Myer Squibb Immune Checkpoint Inhibitors Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 72. Bristol Myer Squibb Product
Table 73. Bristol Myer Squibb Recent Development
Table 74. AstraZeneca Corporation Information
Table 75. AstraZeneca Description and Major Businesses
Table 76. AstraZeneca Immune Checkpoint Inhibitors Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 77. AstraZeneca Product
Table 78. AstraZeneca Recent Development
Table 79. Merck & Co. Corporation Information
Table 80. Merck & Co. Description and Major Businesses
Table 81. Merck & Co. Immune Checkpoint Inhibitors Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 82. Merck & Co. Product
Table 83. Merck & Co. Recent Development
Table 84. Roche / Genentech Corporation Information
Table 85. Roche / Genentech Description and Major Businesses
Table 86. Roche / Genentech Immune Checkpoint Inhibitors Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 87. Roche / Genentech Product
Table 88. Roche / Genentech Recent Development
Table 89. Incyte Corporation Corporation Information
Table 90. Incyte Corporation Description and Major Businesses
Table 91. Incyte Corporation Immune Checkpoint Inhibitors Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 92. Incyte Corporation Product
Table 93. Incyte Corporation Recent Development
Table 94. NewLink Genetics Corporation Information
Table 95. NewLink Genetics Description and Major Businesses
Table 96. NewLink Genetics Immune Checkpoint Inhibitors Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 97. NewLink Genetics Product
Table 98. NewLink Genetics Recent Development
Table 99. ArGEN-X Corporation Information
Table 100. ArGEN-X Description and Major Businesses
Table 101. ArGEN-X Immune Checkpoint Inhibitors Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 102. ArGEN-X Product
Table 103. ArGEN-X Recent Development
Table 104. Seattle Genetics Corporation Information
Table 105. Seattle Genetics Description and Major Businesses
Table 106. Seattle Genetics Immune Checkpoint Inhibitors Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 107. Seattle Genetics Product
Table 108. Seattle Genetics Recent Development
Table 109. Pfizer Corporation Information
Table 110. Pfizer Description and Major Businesses
Table 111. Pfizer Immune Checkpoint Inhibitors Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 112. Pfizer Product
Table 113. Pfizer Recent Development
Table 114. MacroGenics Corporation Information
Table 115. MacroGenics Description and Major Businesses
Table 116. MacroGenics Immune Checkpoint Inhibitors Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 117. MacroGenics Product
Table 118. MacroGenics Recent Development
Table 119. Celldex Therapeutics Corporation Information
Table 120. Celldex Therapeutics Description and Major Businesses
Table 121. Celldex Therapeutics Immune Checkpoint Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 122. Celldex Therapeutics Product
Table 123. Celldex Therapeutics Recent Development
Table 124. CureTech Corporation Information
Table 125. CureTech Description and Major Businesses
Table 126. CureTech Immune Checkpoint Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 127. CureTech Product
Table 128. CureTech Recent Development
Table 129. Immutep Corporation Information
Table 130. Immutep Description and Major Businesses
Table 131. Immutep Immune Checkpoint Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 132. Immutep Product
Table 133. Immutep Recent Development
Table 134. Innate Pharma Corporation Information
Table 135. Innate Pharma Description and Major Businesses
Table 136. Innate Pharma Immune Checkpoint Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 137. Innate Pharma Product
Table 138. Innate Pharma Recent Development
Table 139. Sorrento Therapeutics Corporation Information
Table 140. Sorrento Therapeutics Description and Major Businesses
Table 141. Sorrento Therapeutics Immune Checkpoint Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 142. Sorrento Therapeutics Product
Table 143. Sorrento Therapeutics Recent Development
Table 144. GlaxoSmithKline Corporation Information
Table 145. GlaxoSmithKline Description and Major Businesses
Table 146. GlaxoSmithKline Immune Checkpoint Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 147. GlaxoSmithKline Product
Table 148. GlaxoSmithKline Recent Development
Table 149. GITR, Inc Corporation Information
Table 150. GITR, Inc Description and Major Businesses
Table 151. GITR, Inc Immune Checkpoint Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 152. GITR, Inc Product
Table 153. GITR, Inc Recent Development
Table 154. Global Immune Checkpoint Inhibitors Sales Forecast by Regions (2021-2026) (MT)
Table 155. Global Immune Checkpoint Inhibitors Sales Market Share Forecast by Regions (2021-2026)
Table 156. Global Immune Checkpoint Inhibitors Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 157. Global Immune Checkpoint Inhibitors Revenue Market Share Forecast by Regions (2021-2026)
Table 158. North America: Immune Checkpoint Inhibitors Sales Forecast by Country (2021-2026) (MT)
Table 159. North America: Immune Checkpoint Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 160. Europe: Immune Checkpoint Inhibitors Sales Forecast by Country (2021-2026) (MT)
Table 161. Europe: Immune Checkpoint Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 162. Asia Pacific: Immune Checkpoint Inhibitors Sales Forecast by Region (2021-2026) (MT)
Table 163. Asia Pacific: Immune Checkpoint Inhibitors Revenue Forecast by Region (2021-2026) (US$ Million)
Table 164. Latin America: Immune Checkpoint Inhibitors Sales Forecast by Country (2021-2026) (MT)
Table 165. Latin America: Immune Checkpoint Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 166. Middle East and Africa: Immune Checkpoint Inhibitors Sales Forecast by Country (2021-2026) (MT)
Table 167. Middle East and Africa: Immune Checkpoint Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 168. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 169. Key Challenges
Table 170. Market Risks
Table 171. Main Points Interviewed from Key Immune Checkpoint Inhibitors Players
Table 172. Immune Checkpoint Inhibitors Customers List
Table 173. Immune Checkpoint Inhibitors Distributors List
Table 174. Research Programs/Design for This Report
Table 175. Key Data Information from Secondary Sources
Table 176. Key Data Information from Primary Sources
List of Figures
Figure 1. Immune Checkpoint Inhibitors Product Picture
Figure 2. Global Immune Checkpoint Inhibitors Sales Market Share by Type in 2020 & 2026
Figure 3. PD-1/PD-L1 Product Picture
Figure 4. CTLA-4 Product Picture
Figure 5. Global Immune Checkpoint Inhibitors Sales Market Share by Application in 2020 & 2026
Figure 6. Lung Cancer
Figure 7. Colorectal Cancer
Figure 8. Breast Cancer
Figure 9. Prostate Cancer
Figure 10. Melanoma
Figure 11. Blood Cancer
Figure 12. Other
Figure 13. Immune Checkpoint Inhibitors Report Years Considered
Figure 14. Global Immune Checkpoint Inhibitors Market Size 2015-2026 (US$ Million)
Figure 15. Global Immune Checkpoint Inhibitors Sales 2015-2026 (MT)
Figure 16. Global Immune Checkpoint Inhibitors Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Immune Checkpoint Inhibitors Sales Market Share by Region (2015-2020)
Figure 18. Global Immune Checkpoint Inhibitors Sales Market Share by Region in 2019
Figure 19. Global Immune Checkpoint Inhibitors Revenue Market Share by Region (2015-2020)
Figure 20. Global Immune Checkpoint Inhibitors Revenue Market Share by Region in 2019
Figure 21. Global Immune Checkpoint Inhibitors Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Immune Checkpoint Inhibitors Revenue in 2019
Figure 23. Immune Checkpoint Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Immune Checkpoint Inhibitors Sales Market Share by Type (2015-2020)
Figure 25. Global Immune Checkpoint Inhibitors Sales Market Share by Type in 2019
Figure 26. Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2015-2020)
Figure 27. Global Immune Checkpoint Inhibitors Revenue Market Share by Type in 2019
Figure 28. Global Immune Checkpoint Inhibitors Market Share by Price Range (2015-2020)
Figure 29. Global Immune Checkpoint Inhibitors Sales Market Share by Application (2015-2020)
Figure 30. Global Immune Checkpoint Inhibitors Sales Market Share by Application in 2019
Figure 31. Global Immune Checkpoint Inhibitors Revenue Market Share by Application (2015-2020)
Figure 32. Global Immune Checkpoint Inhibitors Revenue Market Share by Application in 2019
Figure 33. North America Immune Checkpoint Inhibitors Sales Growth Rate 2015-2020 (MT)
Figure 34. North America Immune Checkpoint Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Immune Checkpoint Inhibitors Sales Market Share by Country in 2019
Figure 36. North America Immune Checkpoint Inhibitors Revenue Market Share by Country in 2019
Figure 37. U.S. Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 38. U.S. Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 40. Canada Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Immune Checkpoint Inhibitors Market Share by Type in 2019
Figure 42. North America Immune Checkpoint Inhibitors Market Share by Application in 2019
Figure 43. Europe Immune Checkpoint Inhibitors Sales Growth Rate 2015-2020 (MT)
Figure 44. Europe Immune Checkpoint Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Immune Checkpoint Inhibitors Sales Market Share by Country in 2019
Figure 46. Europe Immune Checkpoint Inhibitors Revenue Market Share by Country in 2019
Figure 47. Germany Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 48. Germany Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 50. France Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 52. U.K. Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 54. Italy Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 56. Russia Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Immune Checkpoint Inhibitors Market Share by Type in 2019
Figure 58. Europe Immune Checkpoint Inhibitors Market Share by Application in 2019
Figure 59. Asia Pacific Immune Checkpoint Inhibitors Sales Growth Rate 2015-2020 (MT)
Figure 60. Asia Pacific Immune Checkpoint Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Immune Checkpoint Inhibitors Sales Market Share by Region in 2019
Figure 62. Asia Pacific Immune Checkpoint Inhibitors Revenue Market Share by Region in 2019
Figure 63. China Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 64. China Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 66. Japan Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 68. South Korea Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 70. India Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 72. Australia Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 74. Taiwan Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 76. Indonesia Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 78. Thailand Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 80. Malaysia Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 82. Philippines Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 84. Vietnam Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Immune Checkpoint Inhibitors Market Share by Type in 2019
Figure 86. Asia Pacific Immune Checkpoint Inhibitors Market Share by Application in 2019
Figure 87. Latin America Immune Checkpoint Inhibitors Sales Growth Rate 2015-2020 (MT)
Figure 88. Latin America Immune Checkpoint Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Immune Checkpoint Inhibitors Sales Market Share by Country in 2019
Figure 90. Latin America Immune Checkpoint Inhibitors Revenue Market Share by Country in 2019
Figure 91. Mexico Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 92. Mexico Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 94. Brazil Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 96. Argentina Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Immune Checkpoint Inhibitors Market Share by Type in 2019
Figure 98. Latin America Immune Checkpoint Inhibitors Market Share by Application in 2019
Figure 99. Middle East and Africa Immune Checkpoint Inhibitors Sales Growth Rate 2015-2020 (MT)
Figure 100. Middle East and Africa Immune Checkpoint Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Immune Checkpoint Inhibitors Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Immune Checkpoint Inhibitors Revenue Market Share by Country in 2019
Figure 103. Turkey Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 104. Turkey Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 106. Saudi Arabia Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E Immune Checkpoint Inhibitors Sales Growth Rate (2015-2020) (MT)
Figure 108. U.A.E Immune Checkpoint Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa Immune Checkpoint Inhibitors Market Share by Type in 2019
Figure 110. Middle East and Africa Immune Checkpoint Inhibitors Market Share by Application in 2019
Figure 111. North America Immune Checkpoint Inhibitors Sales Growth Rate Forecast (2021-2026) (MT)
Figure 112. North America Immune Checkpoint Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Immune Checkpoint Inhibitors Sales Growth Rate Forecast (2021-2026) (MT)
Figure 114. Europe Immune Checkpoint Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Immune Checkpoint Inhibitors Sales Growth Rate Forecast (2021-2026) (MT)
Figure 116. Asia Pacific Immune Checkpoint Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Immune Checkpoint Inhibitors Sales Growth Rate Forecast (2021-2026) (MT)
Figure 118. Latin America Immune Checkpoint Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa Immune Checkpoint Inhibitors Sales Growth Rate Forecast (2021-2026) (MT)
Figure 120. Middle East and Africa Immune Checkpoint Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed
癌チューブリン阻害剤の世界市場（～2026年） Market Analysis and Insights: Global Cancer Tubulin Inhibitors Market The global Cancer Tubulin Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Cancer Tubulin Inhibitors Scope and Market Size Cancer Tubulin …- 癌治療用mTOR阻害剤の世界市場（～2026年） Market Analysis and Insights: Global Cancer mTOR Inhibitors Market The global Cancer mTOR Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Cancer mTOR Inhibitors Scope and Market Size Cancer mTOR Inhibitors m…
- 癌血管新生阻害剤の世界市場（～2026年） Market Analysis and Insights: Global Cancer Angiogenesis Inhibitors Market The global Cancer Angiogenesis Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Cancer Angiogenesis Inhibitors Scope and Market Size …
- 癌治療用ヤヌスキナーゼ阻害剤の世界市場（～2026年） Cancer Janus Kinase Inhibitors The conventional modes of cancer management including surgery, radiotherapy and chemotherapy were discarded as an aspirant for the future of cancer management long back ago. The arrival of modern cancer treatment modalities like immunotherapy and targeted therapy revol…
- 免疫レパートリーシーケンスの世界市場（～2026年） Immune Repertoire is the collection of B and T cells with functional diversity in the body that reflects the immune selectivity. Immune Repertoire Sequencing means to sequence the complimentary determining region of both B-cell receptor and T-cell receptor. Immune receptor repertoire profiling portr…